Oxford BioDynamics (LON:OBD) Stock Price Down 10.2% – Here’s Why

Shares of Oxford BioDynamics Plc (LON:OBD) were down 10.2% during mid-day trading on Friday . The company traded as low as GBX 0.28 and last traded at GBX 0.28. Approximately 27,311,211 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 26,257,648 shares. The stock had previously closed at GBX 0.32.

Oxford BioDynamics Stock Performance

The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The stock’s fifty day moving average is GBX 0.26 and its two-hundred day moving average is GBX 0.36. The firm has a market cap of £12.87 million, a price-to-earnings ratio of -0.38 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last posted its earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.